Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report

Journal of Medical Case Reports

Volumn 11, Issue 1, 2017, Pages

  Kwatra, Vineet ^a   Karanth, Narayan V ^a   Priyadarshana, Kelum ^a,b   Charakidis, Michail ^a  

^a ROYAL DARWIN HOSPITAL   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

Author keywords

Case report; Checkpoint inhibitors; Melanoma; Toxicity; Transplant

Indexed keywords

AZATHIOPRINE; B RAF KINASE; C REACTIVE PROTEIN; EVEROLIMUS; MYCOPHENOLATE MOFETIL; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN SERINE THREONINE KINASE; TACROLIMUS; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; IMMUNOSUPPRESSIVE AGENT; IPILIMUMAB; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CADAVER; CASE REPORT; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE COURSE; END STAGE RENAL DISEASE; HLA TYPING; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN M NEPHROPATHY; IMMUNOHISTOCHEMISTRY; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER BIOPSY; MALE; METASTATIC MELANOMA; MIDDLE AGED; TREATMENT FAILURE; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; COMPLICATION; FATALITY; GRAFT REJECTION; KIDNEY FAILURE, CHRONIC; MELANOMA; PATHOLOGY; SKIN NEOPLASMS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; FATAL OUTCOME; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MELANOMA; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; TREATMENT FAILURE;

EID: 85015411251     PISSN: None     EISSN: 17521947     Source Type: Journal    
DOI: 10.1186/s13256-017-1229-z     Document Type: Article

References (12)

1. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521-32.
2. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123-35.
3. Spain L, Higgins R, Gopalakrishnan K, Turajlic S, Gore M, Larkin J. Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma. Ann Oncol. 2016;27:1135-7.
4. Alhamad T, Venkatachalam K, Linette GP, Brennan DC. Checkpoint inhibitors in kidney transplant recipients and the potential risk of rejection. Am J Transplant. 2016;16:1332-3.
5. Lipson EJ, Bodell MA, Kraus ES, Sharfman WH. Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma. J Clin Oncol. 2014;32:e69-71.
6. Thangavelu G, Murphy KM, Yagita H, Boon L, Anderson CC. The role of co-inhibitory signals in spontaneous tolerance of weakly mismatched transplants. Immunobiology. 2011;216:918-24.
7. Tanaka K, Albin MJ, Yuan X, Yamaura K, Habicht A, Murayama T, et al. PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection. J Immunol. 2007;179:5204-10.
8. Starke A, Lindenmeyer MT, Segerer S, Neusser MA, Rüsi B, Schmid DM, et al. Renal tubular PD-L1 (CD274) suppresses alloreactive human T-cell responses. Kidney Int. 2010;78:38-47.
9. del Rio ML, Buhler L, Gibbons C, Tian J, Rodriguez-Barbosa JI. PD-1/PD-L1, PD-1/PD-L2, and other co-inhibitory signaling pathways in transplantation. Transpl Int. 2008;21:1015-28.
10. Yang HC. Tailoring tacrolimus-based immunotherapy in renal transplantation. Nephrol Dial Transplant. 2003;18 Suppl 1:i16-20.
11. Zwald FO, Christenson LJ, Billingsley EM, Zeitouni NC, Ratner D, Bordeaux J, et al. Melanoma in solid organ transplant recipients. Am J Transplant. 2010;10:1297-304.
12. Lipson EJ, Bagnasco SM, Moore Jr J, Jang S, Patel MJ, Zachary AA, et al. Tumor regression and allograft rejection after administration of anti-PD-1. N Engl J Med. 2016;374:896-8.